Tralokinumab-ldrm Therapeutic Cheat Sheet
162811628116281
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c … Continue reading "Tralokinumab-ldrm Therapeutic Cheat Sheet"
Atopic dermatitis is a heterogeneous, chronic inflammatory disease that affects upwards of 10% of children and 7% of adults in the United States. Despite being an incredibly common skin concern among patients, AD continues to pose diagnostic and treatment challenges to dermatologists.
What are some common misconceptions about AD?
AD always starts in childhood. FALSE. 25% of adults w … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Adam Friedman (Professor and Chair of Dermatology who serves as Associate Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the GW Department of Dermatology) about the latest in Atopic Dermatitis (AD). Watch as he discu … 
With a special focus on atopic dermatitis, the October issue of the Journal of Drugs in Dermatology features a great line up of original articles on topics ranging from topical body skincare for toning and tightening, the psychological burden associated with atopic dermatitis, to treatment of toenail onychomycosis in the US and everything in between! Straight from the JDD Editor’s desk, we sha … 
The following two cases presented by JDD authors Ryan A. Gall MD, John D. Peters MD, and Alyson J. Brinker MD add to the growing literature supporting the use of dupilumab in the treatment of patients with recalcitrant dyshidrotic eczema, both with and without diagnosed contact allergens.
Introduction
Dyshidrotic eczema, also known as dyshidrosis or pompholyx when involving larger bullae, is a c … 